全文获取类型
收费全文 | 3972篇 |
免费 | 251篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 102篇 |
妇产科学 | 81篇 |
基础医学 | 451篇 |
口腔科学 | 169篇 |
临床医学 | 299篇 |
内科学 | 992篇 |
皮肤病学 | 60篇 |
神经病学 | 377篇 |
特种医学 | 85篇 |
外科学 | 713篇 |
综合类 | 26篇 |
一般理论 | 1篇 |
预防医学 | 275篇 |
眼科学 | 91篇 |
药学 | 249篇 |
中国医学 | 4篇 |
肿瘤学 | 226篇 |
出版年
2023年 | 30篇 |
2022年 | 22篇 |
2021年 | 109篇 |
2020年 | 83篇 |
2019年 | 120篇 |
2018年 | 135篇 |
2017年 | 98篇 |
2016年 | 108篇 |
2015年 | 100篇 |
2014年 | 148篇 |
2013年 | 177篇 |
2012年 | 302篇 |
2011年 | 316篇 |
2010年 | 180篇 |
2009年 | 161篇 |
2008年 | 284篇 |
2007年 | 269篇 |
2006年 | 267篇 |
2005年 | 251篇 |
2004年 | 215篇 |
2003年 | 185篇 |
2002年 | 172篇 |
2001年 | 30篇 |
2000年 | 23篇 |
1999年 | 42篇 |
1998年 | 38篇 |
1997年 | 40篇 |
1996年 | 33篇 |
1995年 | 27篇 |
1994年 | 16篇 |
1993年 | 18篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 11篇 |
1985年 | 16篇 |
1984年 | 15篇 |
1983年 | 10篇 |
1982年 | 21篇 |
1981年 | 16篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1975年 | 10篇 |
1974年 | 6篇 |
1973年 | 9篇 |
排序方式: 共有4242条查询结果,搜索用时 15 毫秒
1.
2.
Murat Yücel Erin Oldenhof Serge H. Ahmed David Belin Joel Billieux Henrietta Bowden‐Jones Adrian Carter Samuel R. Chamberlain Luke Clark Jason Connor Mark Daglish Geert Dom Pinhas Dannon Theodora Duka Maria Jose Fernandez‐Serrano Matt Field Ingmar Franken Rita Z. Goldstein Raul Gonzalez Anna E. Goudriaan Jon E. Grant Matthew J. Gullo Robert Hester David C. Hodgins Bernard Le Foll Rico S. C. Lee Anne Lingford‐Hughes Valentina Lorenzetti Scott J. Moeller Marcus R. Munaf Brian Odlaug Marc N. Potenza Rebecca Segrave Zsuzsika Sjoerds Nadia Solowij Wim van den Brink Ruth J. van Holst Valerie Voon Reinout Wiers Leonardo F. Fontenelle Antonio Verdejo‐Garcia 《Addiction (Abingdon, England)》2019,114(6):1095-1109
3.
4.
Velázquez-Pérez Luis Medrano-Montero Jacqueline Rodríguez-Labrada Roberto Canales-Ochoa Nalia Campins Alí Jandy Carrillo Rodes Frank J Rodríguez Graña Tania Hernández Oliver María O. Aguilera Rodríguez Raul Domínguez Barrios Yennis Torres Vega Reydenis Flores Angulo Lissi Cordero Navarro Noharis Y. Sigler Villanueva Aldo A. Gámez Rodríguez Osiel Sagaró Zambrano Ilya Navas Napóles Nayime Y. García Zacarías Javier Serrano Barrera Orlando R. Ramírez Bautista María B. Estupiñán Rodríguez Annelié Guerra Rondón Leonardo A. Vázquez-Mojena Yaimeé González-Zaldivar Yanetza Almaguer Mederos Luis E. Leyva-Mérida Alejandro 《Cerebellum (London, England)》2020,19(2):252-264
The Cerebellum - The prevalence estimations of hereditary ataxias are biased since most epidemiological studies are confined to isolated geographical regions and few nationwide studies are... 相似文献
5.
Ferreli Fabio Mercante Giuseppe De Virgilio Armando Di Maio Pasquale Iocca Oreste Pellini Raul Spriano Giuseppe 《European archives of oto-rhino-laryngology》2020,277(6):1837-1841
European Archives of Oto-Rhino-Laryngology - To analyze the surgical outcomes in terms of postoperative wound complications in a small case series of six patients treated with lateral cervical... 相似文献
6.
Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini 《World journal of gastrointestinal oncology》2015,7(6):47-54
AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads (DEBIRI) and cetuximab (DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma (CRC-LM), progression after first line chemotherapy (any type of chemotherapeutic drug and combination was allowed), second line treatment (mandatory), which included for each patient (unregarding the KRas status) two cycles of DEBIRI (using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status (0-2) and liver functionality (alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/mL). Data were collected retrospectively and included: tumor response (evaluated monthly for 6 mo then every 3 mo), overall response rate (ORR), KRas status, type and intensity of adverse events (G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival (OS) and progression free survival (PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo (range, 4.0-6.5). Sixteen patients (40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders (10%) and 16 (40%) partial responders. The most observed side effects (G2) were: post-embolization syndrome (30%), diarrhea (25%), skin rushes (38%) and asthenia (35%). The retrospective evaluation of KRas status (24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo (8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. 相似文献
7.
8.
9.
10.